ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer

Status unconfirmed · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving ABI-007 together with bevacizumab may kill more tumor cells. PURPOSE: This phase II is studying how well giving ABI-007 together with bevacizumab works in treating women with recurrent or metastatic breast cancer.

Key facts

Study ID

NCT00404404

Run by

Premiere Oncology

People needed

35

Starts

2006-10-01

Last updated by the study team

2013-12-18

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Premiere Oncology — Santa Monica, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.